Entero Therapeutics, Inc. — Investor Relations & Filings

Entero Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic, and orally delivered therapies for gastrointestinal (GI) diseases. The company's portfolio is centered on three proprietary technologies: latiglutenase, a first-in-class oral biotherapeutic designed to degrade gluten for patients with celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for GI indications such as gastroparesis; and adrulipase, a recombinant lipase enzyme to aid fat digestion in patients with exocrine pancreatic insufficiency resulting from cystic fibrosis or chronic pancreatitis. Entero's pipeline addresses a range of digestive disorders and autoimmune-related GI conditions.